🇺🇸 FDA

Company profile · Sponsor

Edgewise

Edgewise Therapeutics

EWTX · NYSE pharma BOULDER, CO, USA
Pipeline
15
Drugs
0
Patents
7

Quick answer

Edgewise (EWTX) is a pharma company. headquartered in BOULDER, CO, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 7 patents to this profile..

Company facts

Ticker EWTX
Exchange NYSE
Company type pharma
Headquarters BOULDER, CO, USA
SEC CIK 0001710072

Pipeline (15)

Search pipeline →

  1. EDG-5506, EDG-5506

    Edgewise

    Becker Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  2. EDG-7500

    Edgewise

    Hypertrophic Cardiomyopathy

    phase 2 small molecule active

    1 trial

  3. Sevasemten

    Edgewise

    Becker Muscular Dystrophy

    phase 2 small molecule active

    2 trials

  4. Sevasemten 10 mg

    Edgewise

    Becker Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  5. Sevasemten Dose 1

    Edgewise

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    2 trials

  6. EDG-15400

    Edgewise

    Healthy Adults

    phase 1 small molecule active

    1 trial

  7. EDG-5506

    Edgewise

    Muscular Dystrophies

    phase 1 small molecule completed

    1 trial

  8. EDG-5506

    Edgewise

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  9. EDG-5506 Tablet

    Edgewise

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  10. EDG-7500

    Edgewise

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  11. EDG-7500

    Edgewise

    Healthy Adult Participants

    phase 1 small molecule active

    1 trial

  12. EDG-7500

    Edgewise

    Hepatic Impairment (HI)

    phase 1 small molecule active

    1 trial

  13. EDG-7500

    Edgewise

    Renal Impairments

    phase 1 small molecule completed

    1 trial

  14. [14C]-EDG-7500

    Edgewise

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  15. sevasemten

    Edgewise

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

Patents (7)

Search patents →

  1. US 12415794

    Pyridazinone compounds and uses thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12240831

    Pyridazinone compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12240833

    Pyridazinone compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12012395

    Pyridazinone compounds and uses thereof

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11390606

    Pyridazinone compounds and uses thereof

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11236065

    Pyridazinone compounds and uses thereof

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11091464

    Pyridazinone compounds and uses thereof

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Edgewise?

Edgewise (EWTX) is a pharma company. headquartered in BOULDER, CO, USA. listed on NYSE. NovaPharmaNews links 15 pipeline programs, 0 drugs, and 7 patents to this profile..

What pipeline programs does Edgewise sponsor?

We track 15 ClinicalTrials.gov-linked programs for Edgewise, including EDG-5506, EDG-5506 and 14 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Edgewise company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.